| __timestamp | BioMarin Pharmaceutical Inc. | Perrigo Company plc |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 675200000 |
| Thursday, January 1, 2015 | 402271000 | 771800000 |
| Friday, January 1, 2016 | 476593000 | 1205500000 |
| Sunday, January 1, 2017 | 554336000 | 1146500000 |
| Monday, January 1, 2018 | 604353000 | 1125800000 |
| Tuesday, January 1, 2019 | 680924000 | 1166100000 |
| Wednesday, January 1, 2020 | 737669000 | 1175500000 |
| Friday, January 1, 2021 | 759375000 | 1111400000 |
| Saturday, January 1, 2022 | 854009000 | 1210100000 |
| Sunday, January 1, 2023 | 937300000 | 1274600000 |
| Monday, January 1, 2024 | 1009025000 |
In pursuit of knowledge
In the competitive landscape of pharmaceuticals, understanding spending patterns is crucial. BioMarin Pharmaceutical Inc. and Perrigo Company plc have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, BioMarin's SG&A expenses surged by approximately 210%, reflecting a strategic investment in growth and market expansion. In contrast, Perrigo's expenses increased by about 89%, indicating a more conservative approach.
BioMarin's aggressive spending, peaking at nearly 938 million in 2023, underscores its commitment to innovation and market penetration. Meanwhile, Perrigo's steady rise to 1.27 billion suggests a focus on maintaining operational efficiency while expanding its product portfolio. These financial strategies highlight the diverse approaches companies take to thrive in the pharmaceutical industry, offering valuable insights for investors and stakeholders.
Breaking Down SG&A Expenses: Bristol-Myers Squibb Company vs Perrigo Company plc
Comparing SG&A Expenses: Gilead Sciences, Inc. vs Perrigo Company plc Trends and Insights
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Walgreens Boots Alliance, Inc.
Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Alpine Immune Sciences, Inc.
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs TG Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Rhythm Pharmaceuticals, Inc.
Exelixis, Inc. and Perrigo Company plc: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Opthea Limited or Perrigo Company plc
Selling, General, and Administrative Costs: CRISPR Therapeutics AG vs Perrigo Company plc
Perrigo Company plc or Amicus Therapeutics, Inc.: Who Manages SG&A Costs Better?
Perrigo Company plc vs MorphoSys AG: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Perrigo Company plc and Viridian Therapeutics, Inc.